dostarlimab,trastuzumab deruxtecan
gsk,daiichi sankyo,astrazeneca
['breast', 'rectal', 'dostarlimab']
starting #asco22 day 3 with two practice-changing publications in dostarlimab in locally advanced rectal cancer t-dxd in her2-low metastatic breast cancer 
M.D. - Research Fellow @MSKCancerCenter | Former Medical Oncology Fellow @LaStatale @IEOufficiale | Interested in #genomics #bioinformatics #AI #bcsm #newdrugs